Floatz logo

tbm100

Pseudomonas Aeruginosa in Cystic Fibrosis

Novartis PharmaceuticalsPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

82 Active assets in the Pseudomonas Aeruginosa in Cystic Fibrosis cohort.

Asset / SponsorPhaseRating
Tezacaftor
Vertex Pharmaceuticals Incorporated
Phase 4A
Liprotamase
Anthera Pharmaceuticals
Phase 4BBB
Lumacaftor
Hospices Civils de Lyon
Phase 4BBB
Ivacaftor
Meyer Children's Hospital IRCCS
Phase 4BBB
ELEXACAFTOR
Meyer Children's Hospital IRCCS
Phase 4BBB

View all 50 →

Same molecule, other indications

tbm100 is also rated in:

Long-term Safety of TIPDormant
NR
Indicative ·
/ 100
View asset →
pneumoniaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →